Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

AbbVie Inc (4AB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
151.40 -1.60    -1.05%
02:19:33 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US00287Y1091 
S/N:  A1J84E
  • Volume: 0
  • Bid/Ask: 151.12 / 152.58
  • Day's Range: 151.40 - 151.40
AbbVie 151.40 -1.60 -1.05%

AbbVie Inc Company Profile

 
Get an in-depth profile of AbbVie Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

50000

Equity Type

ORD

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Contact Information

Address 1 North Waukegan Road
North Chicago, 60064-6400
United States
Phone 847 932 7900
Fax -

Top Executives

Name Age Since Title
Richard A. Gonzalez 67 2013 Chairman & CEO
Edward Joseph Rapp 65 2013 Independent Director
William H. L. Burnside 71 2013 Independent Director
Roxanne S. Austin 62 2013 Independent Director
Glenn F. Tilton 75 2013 Lead Independent Director
Thomas Craig Freyman 69 2020 Independent Director
Robert J. Alpern 72 2013 Independent Director
Frederick H. Waddell 69 2013 Independent Director
Rebecca B. Roberts 70 2018 Independent Director
Melody Boone Meyer 65 2017 Independent Director
Brett J. Hart 53 2016 Independent Director
Susan E. Quaggin 60 2023 Independnet Director
Jennifer L. Davis 52 2023 Independnet Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABBV Comments

Write your thoughts about AbbVie Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Bryan Shipley
Bryan Shipley Mar 19, 2024 10:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And the final blow... the 5 dma is now below the 12 dma, time for a much bigger fall 😱
Bryan Shipley
Bryan Shipley Mar 15, 2024 11:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And NOW you see what happens after MoneyFlow and FullSto have crossed negative
Bryan Shipley
Bryan Shipley Mar 14, 2024 9:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
169, I'm ready 💪
Ron West
Ron West Dec 28, 2023 8:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hold on, 2024 looks positive.
Bryan Shipley
Bryan Shipley Dec 11, 2023 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Beginning to become overbought, when FULL STO turns negative it will be time to take some profits IMHO
Ron West
Ron West Dec 11, 2023 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
maybe not yet!
Ron West
Ron West Dec 11, 2023 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hope you stayed in!
Nilesh Khupase
Nilesh Khupase Aug 08, 2023 3:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Best divident and growth stock ever
Nilesh Khupase
Nilesh Khupase Aug 08, 2023 3:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
# Dividend
Ron West
Ron West Aug 08, 2023 3:40PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
still is.
Ron West
Ron West Apr 17, 2023 9:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
John Zeman
John Zeman Apr 17, 2023 9:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lmao
Ron West
Ron West Apr 17, 2023 9:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tom Investor
Tom Investor Jan 20, 2023 4:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jbjhjb
Ron West
Ron West Dec 30, 2022 11:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
we'll get em next year.
Ron West
Ron West Nov 14, 2022 5:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I remain a believer.
Zsolt Barabás
Zsolt Barabás Nov 14, 2022 5:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Me too.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email